This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Biotage マネジメント
マネジメント 基準チェック /34
現在、CEO に関する十分な情報がありません。
主要情報
Frederic Vanderhaegen
最高経営責任者
SEK 8.3m
報酬総額
| CEO給与比率 | 20.81% |
| CEO在任期間 | less than a year |
| CEOの所有権 | n/a |
| 経営陣の平均在職期間 | 3.2yrs |
| 取締役会の平均在任期間 | 3.6yrs |
経営陣の近況
Recent updates
分析記事 • Apr 08
Biotage's (STO:BIOT) Dividend Will Be Increased To SEK1.65
The board of Biotage AB (publ) ( STO:BIOT ) has announced that it will be paying its dividend of SEK1.65 on the 2nd of...分析記事 • Mar 05
Biotage AB (publ)'s (STO:BIOT) Popularity With Investors Under Threat As Stock Sinks 26%
To the annoyance of some shareholders, Biotage AB (publ) ( STO:BIOT ) shares are down a considerable 26% in the last...分析記事 • Feb 20
Is Biotage (STO:BIOT) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
新しいナラティブ • Feb 09
New Product Launches And Focus On High-Growth Areas Will Strengthen Future Prospects
Expansion in manufacturing capacity and new product launches are likely to drive revenue growth and reduce backlog.分析記事 • Nov 16
Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 48%?
Key Insights The projected fair value for Biotage is kr288 based on 2 Stage Free Cash Flow to Equity Current share...分析記事 • Oct 26
Earnings Miss: Biotage AB (publ) Missed EPS By 15% And Analysts Are Revising Their Forecasts
Biotage AB (publ) ( STO:BIOT ) missed earnings with its latest third-quarter results, disappointing overly-optimistic...分析記事 • Sep 17
Investors Interested In Biotage AB (publ)'s (STO:BIOT) Earnings
Biotage AB (publ)'s ( STO:BIOT ) price-to-earnings (or "P/E") ratio of 58.6x might make it look like a strong sell...分析記事 • Jul 19
Biotage AB (publ) Just Missed EPS By 7.7%: Here's What Analysts Think Will Happen Next
It's been a pretty great week for Biotage AB (publ) ( STO:BIOT ) shareholders, with its shares surging 12% to kr190 in...分析記事 • Jun 08
Are Investors Undervaluing Biotage AB (publ) (STO:BIOT) By 39%?
Key Insights Biotage's estimated fair value is kr290 based on 2 Stage Free Cash Flow to Equity Biotage's kr176 share...分析記事 • May 21
Is Biotage AB (publ) (STO:BIOT) Potentially Undervalued?
Biotage AB (publ) ( STO:BIOT ), is not the largest company out there, but it saw a decent share price growth of 19% on...分析記事 • Apr 28
Revenue Beat: Biotage AB (publ) Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates
Investors in Biotage AB (publ) ( STO:BIOT ) had a good week, as its shares rose 4.4% to close at kr166 following the...分析記事 • Apr 17
Biotage's (STO:BIOT) Dividend Will Be SEK1.60
Biotage AB (publ)'s ( STO:BIOT ) investors are due to receive a payment of SEK1.60 per share on 3rd of May. This means...分析記事 • Apr 08
Biotage AB (publ) Just Beat EPS By 53%: Here's What Analysts Think Will Happen Next
Biotage AB (publ) ( STO:BIOT ) just released its yearly report and things are looking bullish. The company beat...分析記事 • Apr 03
Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60
Biotage AB (publ)'s ( STO:BIOT ) investors are due to receive a payment of SEK1.60 per share on 3rd of May. This makes...分析記事 • Mar 04
Biotage (STO:BIOT) Has Announced A Dividend Of SEK1.60
Biotage AB (publ) ( STO:BIOT ) has announced that it will pay a dividend of SEK1.60 per share on the 3rd of May. This...分析記事 • Feb 22
Weak Statutory Earnings May Not Tell The Whole Story For Biotage (STO:BIOT)
The market rallied behind Biotage AB (publ)'s ( STO:BIOT ) stock, leading do a rise in the share price after its recent...分析記事 • Feb 21
Subdued Growth No Barrier To Biotage AB (publ) (STO:BIOT) With Shares Advancing 32%
Despite an already strong run, Biotage AB (publ) ( STO:BIOT ) shares have been powering on, with a gain of 32% in the...分析記事 • Feb 18
Biotage AB (publ) Just Recorded A 53% EPS Beat: Here's What Analysts Are Forecasting Next
Biotage AB (publ) ( STO:BIOT ) investors will be delighted, with the company turning in some strong numbers with its...分析記事 • Feb 08
Biotage (STO:BIOT) Has A Pretty Healthy Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Jan 07
Investors Still Waiting For A Pull Back In Biotage AB (publ) (STO:BIOT)
With a price-to-earnings (or "P/E") ratio of 53.5x Biotage AB (publ) ( STO:BIOT ) may be sending very bearish signals...分析記事 • Dec 08
At kr124, Is It Time To Put Biotage AB (publ) (STO:BIOT) On Your Watch List?
While Biotage AB (publ) ( STO:BIOT ) might not be the most widely known stock at the moment, it received a lot of...分析記事 • Oct 27
Estimating The Intrinsic Value Of Biotage AB (publ) (STO:BIOT)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Biotage fair value estimate is kr123 With kr109 share price...分析記事 • Jul 12
Does Biotage (STO:BIOT) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Jun 08
An Intrinsic Calculation For Biotage AB (publ) (STO:BIOT) Suggests It's 26% Undervalued
Key Insights Biotage's estimated fair value is kr203 based on 2 Stage Free Cash Flow to Equity Current share price of...分析記事 • May 24
Biotage (STO:BIOT) Ticks All The Boxes When It Comes To Earnings Growth
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...分析記事 • Apr 05
Biotage's (STO:BIOT) Upcoming Dividend Will Be Larger Than Last Year's
Biotage AB (publ) ( STO:BIOT ) will increase its dividend from last year's comparable payment on the 5th of May to...分析記事 • Mar 12
These 4 Measures Indicate That Biotage (STO:BIOT) Is Using Debt Safely
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Feb 21
Is It Too Late To Consider Buying Biotage AB (publ) (STO:BIOT)?
Biotage AB (publ) ( STO:BIOT ), is not the largest company out there, but it saw a double-digit share price rise of...CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | SEK 255m |
| Dec 31 2024 | SEK 8m | SEK 2m | SEK 284m |
報酬と市場: Fredericの 総報酬 ($USD 875.35K ) は、 Swedish市場 ($USD 1.19M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Fredericの報酬と会社の業績を比較するにはデータが不十分です。
CEO
Frederic Vanderhaegen (58 yo)
less than a year
在職期間
SEK 8,326,457
報酬
Mr. Frederic Vanderhaegen is Chief Executive Officer & President of Biotage AB (publ) from September 16, 2024. Mr. Vanderhaegen joined the Biotage AB (publ) on September 16, 2024. Mr. Frederic was Executiv...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chief Executive Officer & President | less than a year | SEK 8.33m | データなし | |
| Chief Financial Officer | 1.8yrs | データなし | データなし | |
| Chief Operating Officer | no data | データなし | 0.011% SEK 1.2m | |
| Chief Scientific Officer | no data | データなし | データなし | |
| EVP of Global Marketing | no data | データなし | データなし | |
| Chief Human Resources & Sustainability Officer | no data | データなし | データなし | |
| Executive Vice President of Operations | no data | データなし | データなし | |
| President of International - EMEA and APAC | 5.1yrs | データなし | データなし | |
| Executive Vice President of IT & Digitalization | no data | データなし | データなし | |
| Executive Vice President of Quality Assurance & Regulatory Affairs | 4.5yrs | データなし | データなし | |
| CEO of Cardiff Production Facility & Global Head of Environmental Working Group | no data | データなし | データなし |
3.2yrs
平均在職期間
53.5yo
平均年齢
経験豊富な経営陣: BIOTの経営陣は 経験豊富 であると考えられます ( 3.2年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Director | 5.7yrs | SEK 14.51m | 0.40% SEK 45.9m | |
| Chairman | 2.3yrs | SEK 882.00k | データなし | |
| Director | 12.3yrs | SEK 460.00k | 0.45% SEK 51.4m | |
| Director | 5.7yrs | SEK 373.00k | データなし | |
| Director | 6.3yrs | SEK 320.00k | 0.00015% SEK 17.2k | |
| Director | 2.3yrs | SEK 240.00k | データなし | |
| Employee Representative Director | 3.6yrs | データなし | データなし | |
| Director | 3.3yrs | SEK 353.00k | データなし | |
| Employee Representative Director | no data | データなし | データなし | |
| Employee Representative Director | 1.5yrs | データなし | データなし |
3.6yrs
平均在職期間
62.5yo
平均年齢
経験豊富なボード: BIOTの 取締役会 は 経験豊富 であると考えられます ( 3.6年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2025/07/23 03:37 |
| 終値 | 2025/07/21 00:00 |
| 収益 | 2025/03/31 |
| 年間収益 | 2024/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Biotage AB (publ) 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3
| アナリスト | 機関 |
|---|---|
| Samuel England | Berenberg |
| Odysseas Manesiotis | Berenberg |
| Marcus Bellander | Carnegie Investment Bank AB |